CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 494 enrolled
Drug / intervention
Albiglutide 30 mg weekly +3 moredrug
Likely dose
Albiglutide 30 mg weeklyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01733758
NCT01733758Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus

GlaxoSmithKline·interventional·Posted Nov 27, 2012·Updated Sep 22, 2016

In Brief

A Phase 3 clinical trial evaluating Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 494 participants across 74 sites.

Detailed Summary

This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 27, 2012
Enrollment StartFeb 1, 2013
Primary CompletionJun 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.6 years ago

Interventions

Albiglutide 30 mg weeklydrug

Albiglutide will be available as a pen injector that delivers 30mg of albiglutide

Albiglutide 50 mg weeklydrug

Albiglutide will be available as a pen injector that delivers 50mg of albiglutide

Placebodrug

Albiglutide matching placebo will be available as a pen injector

Liraglutide 0.9 mg dailydrug

Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose